Context and objective: Insulin acts in the brain to reduce food intake and body weight and is considered a major adiposity signal in energy homeostasis. In normal-weight men, intranasal insulin administration reduces body fat and improves declarative memory. The present experiments aimed to generalize these findings to obese patients, with a view to evaluate the therapeutic potential of the compound. Design, subjects and measurements: Insulin and placebo, respectively, were intranasally administered four times a day (amounting to 160 IU day À1 ) over 8 weeks to two groups of 15 obese men each. Results: Contrasting with the catabolic effects in normal-weight men, insulin treatment did not induce any significant reduction of body weight (P40.50) and body fat (P40.44) in the obese subjects. However, in accordance with the effects in normalweight men, declarative memory and mood were improved (Po0.05) and hypothalamic-pituitary-adrenal axis activity as assessed by circulating ACTH (Po0.01) and cortisol levels (Po0.04) was reduced. Conclusions: Our results indicate that in obese men, intranasal insulin is functionally active in the central nervous system but fails to affect the neuronal networks critically involved in body weight regulation. We conclude that obesity in men is associated with central nervous resistance to the adiposity signal insulin. This defect likely contributes to the persistence of obesity in spite of elevated levels of circulating insulin in obese patients.
Introduction
Obesity rates are rising on a global scale while therapeutic strategies against this epidemic so far have remained rather ineffective. 1 Still, research on the neuroendocrine control of energy metabolism has made considerable progress, identifying the neuropeptides leptin and insulin as two major adiposity signals that convey to the brain the amount of energy stored as body fat. 2 Administration of insulin to the central nervous system (CNS) reduces food intake and body weight. 3, 4 Moreover, insulin administration enhances memory functions in rats 5 and humans, [6] [7] [8] [9] indicating that CNS insulin signaling is also involved in cognitive functioning. Circulating insulin accesses the CNS primarily via a saturable, active transport across the blood-brain barrier. 10 Animal data indicate that insulin transport to the brain is hampered in the obese state, resulting in a relative CNS deficit of the adiposity signal insulin in genetic and dietinduced models of obesity. 11, 12 In humans, obesity appears to be associated with a comparable lack in CNS insulin. 13 Intranasal administration of insulin bypasses the bloodbrain barrier, increasing the concentration of the compound in cerebrospinal fluid without absorption into the blood stream. 14 Accordingly, intranasally administered neuropeptides have been shown to effectively accumulate in rat brain tissue. 15 In a previous study, 8 weeks of intranasal insulin administration (160 IU day
À1
) induced loss of body weight and fat mass in conjunction with decreased leptin levels in normal-weight men but not in women. 16 In addition, insulin treatment improved hippocampus-dependent declarative memory and mood in male and female subjects. 9 The present experiments aimed at generalizing these findings to obese men, examining if enhancing the availability of insulin in the CNS by intranasal administration might have therapeutic potential in the treatment of obesity. Also, we assessed mood and tested declarative memory functions by means of a word list that subjects had to learn and recall.
Subjects, materials and methods

Subjects
Thirty obese men participated in the experiments. They were non-smokers and free of medication. Chronic and acute illness was excluded by clinical examination and routine laboratory tests. Subjects abstained from alcohol, caffeine and food for 12 h before each testing. ) in the pre-testing examination. During 2 weeks of baseline, all subjects received placebo. During the following 8-week treatment epoch, subjects were intranasally administered either insulin or placebo four times a day: in the morning, around noon, in the evening (B30 min before mealtime, respectively) and before going to bed. Each dose consisted of 0.4 ml insulin (40 IU; Insulin Actrapid HM, Novo Nordisk, Mainz, Germany) or vehicle (HOE 31 dilution buffer for H-Insulin, Sanofi-Aventis, Frankfurt, Germany) administered within four puffs of 0.1 ml (two per nostril), amounting to 1.6 ml (160 IU) insulin or vehicle per day. This dose regimen had been proven effective in reducing body weight and improving declarative memory in previous studies. 9, 16 Sprays were stored at B5 1C and were replaced every week. To assure compliance, subjects kept a diary on their intake routine and were told that irregular intake would be detected via urine sampling. Diaries and weekly interviews did not provide any evidence that the obese subjects of this study more frequently forgot to take the spray than lean subjects of previous studies. 9, 16 Test sessions, scheduled between 0700 and 0900 hours, took place at the beginning (session A) and end (B) of the baseline phase and after 4 and 8 weeks of treatment (C and D, respectively), each time following the administration of placebo, except for session B where the treatment group for the first time received insulin to detect possible acute effects. Subjects were informed that the study aimed at the effects of intranasal insulin on cognitive functions.
Physical examination
Immediately after substance administration, subjects were weighed and their body composition was measured by standard bioelectrical impedance analysis (frequencies of 1, 5, 50 and 100 Hz; BIA 2000-M and Eurobody Software, Data Input GmbH, Frankfurt, Germany). Also, waist circumference was measured. Resting energy expenditure was registered using indirect calorimetry (DeltatracTM II, MBM-200 Metabolic Monitor, Datex-Engström Deutschland GmbH, Achim, Germany). Heart-rate variability was measured simultaneously for an interval of 20 min (12 lead simultaneous ECG, sampling rate 1000 Hz, ECG labTM Version 2.0, Meigaoyi Co., Beijing, China). Sixty minutes after substance administration, blood samples were taken for determination of leptin, insulin, glucose, adrenocorticotropic hormone (ACTH) and cortisol. Epinephrine and norepinephrine in 12-h nocturnal collection urine (2000-0800 hours) were measured by standard high-performance liquid chromatography. Between test sessions A and D, weekly examinations at 0800 hours allowed the determination of body weight, blood sampling and for the control of possible side effects on blood pressure, heart rate and routine laboratory measures.
Cognitive tests
In sessions A and B and in a session taking place 1 week before D (DÀ1 week), cognitive tests were performed and mood was assessed 60 min after administration of placebo (A, DÀ1 week) and insulin (B), respectively. Delayed memory recall was tested 1 week later (A þ 1 week, B þ 1 week, D), each time 60 min after placebo. Also, subjects rated their hunger, thirst and tiredness on 10-point scales before the cognitive tasks and at the end of the session, yielding gradients of hunger, thirst and tiredness across each session.
Declarative memory
As an indicator of hippocampus-dependent declarative memory, conscious recollection of facts was tested by means of a word list that subjects had to learn and recall. 9, 17 Thirty words of three semantic categories, neutral (for example, 'tree'), food-related (for example, 'ham') and emotional (for example, 'friend'), were presented orally at a rate of 1 word per second. After 3 min, subjects wrote down all words they remembered within 90 s (immediate recall). One week later, subjects again reported all words they still remembered (delayed recall).
Nondeclarative memory
Nondeclarative memory, which is mainly expressed implicitly through performance rather than conscious recollection and does not depend on hippocampal functioning, 18 was assessed by a wordstem priming task. 9, 19 At acquisition, subjects rated 52 nouns (learning list) according to their pleasantness on a five-point scale. This task was considered to induce implicit learning. Thereafter, subjects received the test list containing 52 two-letter wordstems. Twenty-six of Brain insulin signaling in obesity M Hallschmid et al those were derived from the learning list and 26 wordstems were taken from a pool of new words (new list). Subjects completed the wordstems to the first noun they could think of. One week later (delayed recall), a second list with wordstems derived from the remaining words of the learning list and the new list (26 words each) was filled in by the subjects. The difference between the number of wordstems completed to nouns from the learning list and the number of words accidentally completed to nouns of the new list was considered a measure of implicit memory.
Mood
Subjects filled in an adjective check list assessing mood and aspects of activation on 15 dimensions including activation, deactivation, fatigue, numbness, extroversion, introversion, self-assuredness, well-being, agitation, sensibility, anger, anxiousness, depressiveness and dreaminess. For each adjective, the subject had to indicate whether or not it reflected his/her current state of mood. 20 
Selective attention
The Stroop test is a neuropsychological measure of selective attention. 21 After the word reading and the color naming tests (for description see Benedict et al.
9
), in the interference subtest subjects were presented a series of color names (green, red, blue and yellow) printed in different colors. Their task was to name as quickly as possible the color of the ink in which each word was printed, but to inhibit the prepotent reading response. For each test, the total number of correct responses within 45 s was determined.
Assays
Blood samples were centrifuged immediately, and the plasma was stored at À20 1C. Concentrations of insulin, ACTH and cortisol were measured using standard enzymelinked immunoassays (Immulite, DPC, Los Angeles, CA, USA). Leptin was assessed by enzyme-linked immunosorbent assay (DSL, Webster, TX, USA). Glucose was measured in fluoride plasma (Aeroset, Abbott, Wiesbaden, Germany).
Statistical analyses
Values were baseline adjusted by subtracting the individual mean values during the 2 weeks baseline phase from the treatment values. Analyses relied on analyses of variance for repeated measures (between-subject factor: treatment; within-subject factor: time) and subsequent t-tests to detect significant differences between conditions at single time points. For the cognitive tests, difference values were analyzed separately to discern acute (session B) from long-term treatment effects. All values are indicated as means7s.e.m. Pp0.05 was considered significant.
Results
Intranasal insulin treatment did not induce changes in body weight, body fat ( Figure 1 ) and measures of body composition (Table 1) . Heart rate in the insulin group decreased during treatment (F(1,28) ¼ 5.00, Po0.03 for analysis of variance treatment effect), but this might be a consequence of relatively high baseline values of this group (Table 1) Brain insulin signaling in obesity M Hallschmid et al
All other parameters including resting energy expenditure and heart rate variability also remained unaffected (Table 1) . After 8 weeks of insulin administration, delayed recall of a word list learned 1 week before was enhanced in comparison to placebo. This held for recall of neutral words (Po0.05) and for the sum of recalled words from each word category (Po0.05; Figure 1 ), whereas retrieval of emotional (P ¼ 0.19) and food-related words (P ¼ 0.68) per se seemed less affected (Table 2 ). However, there was no significant interaction between the factors treatment and word category at all time points of assessment (P40.56, for all comparisons). Immediate recall after acute (session B) and after 7 weeks of insulin administration (session DÀ1 week) as well as delayed recall after only 1 week of treatment was not affected (Table 2) . Nondeclarative memory as assessed by a wordstem priming task was altered neither after acute (P40.24 for all comparisons) nor after long-term administration (P40.57). The results of the mood adjective check list revealed that acute administration of insulin decreased the level of introversion (session B, insulin vs placebo, 0.3470.27 vs 1.287 0.26, Po0.02) and anxiousness (0.1270.29 vs 0.9570.28, Po0.05). There was also a trend toward improved concentration Abbreviations: ANOVA, analysis of variance; BMI, body mass index; HRV LF/HF, heart rate variability expressed as the ratio of low to high frequency power; REE, resting energy expenditure. Means (7s.e.m.) after 4 (session C) and 8 weeks (session D) of intranasal insulin treatment. Baseline indicates mean values during 2 weeks of initial placebo administration. Hunger gradient: difference between hunger ratings 60 min after insulin administration and at the end of examination. The right column indicates P-values for overall treatment effects (ANOVA; differences to baseline were compared between groups). N ¼ 15 for each group. Significant P-values are indicated in bold. (Figure 2) . Correspondingly, intranasal insulin decreased serum cortisol levels (F(1,28) ¼ 5.10, Po0.04, for treatment). This effect was even more pronounced, reaching significance or near significance at all time points except at 4 and 5 weeks of treatment (Figure 2 ). Leptin levels were not affected by insulin (F(1,28) ¼ 0.26, P ¼ 0.62 for treatment). The same holds for insulin (F(1,28) ¼ 0.56, P ¼ 0.46) and plasma glucose levels (F(1,28) ¼ 1.26, P ¼ 0.27), indicating that intranasal insulin did not reach the circulation in substantial amounts (Table 1) . Epinephrine and norepinephrine levels remained completely unchanged (F(1,28) ¼ 0.00, P ¼ 0.99; F(1,28) ¼ 0.30, P ¼ 0.57, respectively), excluding pronounced increases in sympathetic tone after insulin treatment.
Discussion
Eight weeks of intranasal insulin administration failed to reduce body weight and body fat in obese men, but improved declarative memory as well as mood and suppressed the activity of the hypothalamicFpituitary-adrenal (HPA) axis as assessed by circulating ACTH and cortisol. The effects on memory and HPA axis activity corroborate similar observations in normal-weight male subjects. 9 In contrast, lean men also lost body fat and body weight. Thus, intranasal insulin affects brain functions in obese men similar to lean men, sparing, however, the networks that mediate insulin's effects on body weight regulation. This outcome indicates that obesity in men is associated with central nervous resistance against the adiposity signal insulin. The reduction in morning plasma ACTH and serum cortisol levels indicates that elevated CNS insulin suppresses HPA axis activity. A similar effect was found in normalweight subjects after 8 weeks of intranasal insulin. 9 These results point to diverging effects of insulin at central and peripheral levels of the HPA axis because the elevation of circulating insulin levels during a euglycemic hyperinsulinemic clamp stimulates rather than decreases HPA activity. 22 Intranasal insulin may suppress HPA axis activity by enhancing corticosteroid feedback processing in the hippocampus, 23 a brain structure considered to exert an inhibiting control over the HPA system via projections to the hypothalamus. 24 Interactions with signals like atrial natriuretic peptide that are assumed to inhibit hypothalamic ACTH release may add to this effect. 25 As observed in normalweight men, 16, 26 the transient increase in systolic blood pressure after acute insulin administration vanished during long-term treatment. After 8 weeks of insulin treatment, declarative memory as assessed by delayed recall of words learnt 1 week earlier was significantly improved. This result robustly replicates the beneficial effect of intranasal insulin on declarative memory seen in normal-weight men and women 8, 9 as well as findings in animals where intracerebroventricular administration of the compound enhanced memory functions. 5, 27 Declarative memory comprises the acquisition and recall of facts and events. Its formation relies primarily on (white bars/circles). Hormone levels at À2 weeks, after acute administration (0 week), and at 4 and 8 weeks (depicted as bars) are generally lower because subjects rested for around 60 min before blood sampling. 28 In these structures, insulin increases long-term potentiation and promotes neuronal outgrowth, that is, plastic mechanisms supposed to underlie memory functions at the neuronal level. 27 The slow onset of memory enhancement by intranasal insulin in the absence of acute effects speaks for the involvement of gradual plastic neuronal changes. Enhancement of neuronal glucose utilization by insulin 29 as well as the observed suppression of cortisol release may have further supported memory improvement. 30 Glucocorticoids can inhibit synaptic long-term potentiation and decrease hippocampal glutamate turnover by binding to hippocampal glucocorticoid receptors. 31 Also, long-term increases in corticosteroids are associated with reduced branching of hippocampal dendrites. 32 Conversely, the reduction of cortisol by intranasal insulin may enhance declarative memory formation. 33 In accordance with previous results in normal-weight subjects, 9,34 insulin treatment also improved mood as reflected by decreased scores of introversion and anxiousness and trends toward reduced depressiveness and anger, corroborating that obese men are sensitive to the improving effects of intranasal insulin on neuropsychological functions. Intranasal insulin treatment did not reduce body fat and body weight in obese men. This outcome is strikingly different from the results in normal-weight men where the same treatment reduced hunger and induced a distinct loss of body fat and body weight. 16 It can be concluded that besides impaired blood-to-brain transport of insulin [11] [12] [13] that in our experiments was overridden by the intranasal administration of the compound, obesity is associated with central nervous resistance against the adiposity signal insulin not only in animals, but also in humans. Concordantly, intranasal insulin failed to acutely suppress food intake in obese men. 35 In rats, the catabolic impact of intracerebroventricular insulin and leptin is curbed in animals with diet-induced obesity, [36] [37] [38] suggesting that central nervous resistance against both endogenous adiposity signals essentially contributes to obesity. Interestingly, in our previous studies 9, 16 normal-weight women displayed memory improvement but did not lose body fat due to intranasal insulin, which is a pattern similar to the effects seen in the obese men of present experiments. In accordance, female rats are less sensitive to the catabolic action of intracerebroventricular insulin and more sensitive to that of intracerebroventricular leptin than male rats, indicating that in men, catabolic brain insulin signaling plays a more important role than in women. 39, 40 In vitro studies have indicated insulin resistance in hippocampal slices of female obese Zucker rats, 41 but it remains to be systematically elucidated if the sex difference observed in the normalweight state also pertains to central nervous insulin and leptin resistance in obesity. Recently, a magnetoencephalographic study has shown that the cerebrocortical responsiveness to acute hyperinsulinemia is diminished in overweight men and women. 42 At first glance, this outcome seems at odds with the fact that after 8 weeks of treatment, our obese subjects displayed preserved susceptibility to insulin's improving effect on delayed word list recall in as much the storage of declarative memory representations involves also neocortical brain areas. 18 However, neither in the present nor in our previous studies did intranasal insulin administration exert any acute effect on memory function in lean men. 8, 9 This lack in acute effect of intranasal insulin in fact indicates that the observed insulin-induced enhancement in memory is conveyed by plastic neuronal processes (for example, synaptic sprouting) that need extended time periods to become behaviorally effective. Moreover, such effects can develop entirely independently from any acute effects of insulin on the neocortical response to sensory stimuli. 42 Going beyond the examination of acute insulin effects, our data show that long-term enhancement of brain insulin signaling, while affecting cognition and HPA axis activity in obese men in the same manner as in lean men, 9 does not reduce body weight.
This pattern strongly supports the notion that primarily, central nervous insulin resistance in obese men focuses on brain structures relevant to the regulation of energy homeostasis. Fittingly, a partial decrease in insulin receptors that selectively pertain to the hypothalamic arcuate nucleus has been shown to markedly impair energy balance and peripheral insulin action in rats. 43 On a molecular level, a defect in the insulin receptor substrate-phosphatidylinositol 3-OH kinase (IRS-PI3K) pathway is likely to be one mechanism of such local neuronal insulin resistance.
2,44
Taken together, our results indicate that in men, insulin resistance in central nervous structures that regulate food intake and body weight contributes to the development of obesity and to its persistence despite the elevation of peripheral insulin levels that is associated with obesity and that otherwise might be expected to reduce food intake via negative feedback to the brain. Although ineffective at reducing body weight in the obese state, by suppressing HPA axis activity intranasal insulin could counteract the development of peripheral insulin resistance and visceral obesity that are promoted by excessive HPA axis secretion related to chronic stress. 45, 46 Likewise, it is possible that the compound gains impact on weight regulatory mechanisms only after successful weight loss has been achieved (for example, by caloric restriction and exercise), and in this case may prevent regain of weight. 47 
